GC
OCRX

Guggenheim Capital’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Guggenheim Capital’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,622
Closed -$9K – 3227
2013
Q2 		$9K Buy
+1,622
New +$10.1K ﹤0.01% 3018

Other funds holding OCRX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Guggenheim Capital's OCRX Position: Q3 2013 in Review

Guggenheim Capital sold out of Ocera Therapeutics, Inc. (OCRX) in Q3 2013, closing a stake of 1,622 shares — an estimated $9K sold.

Guggenheim Capital first reported a position in OCRX in Q2 2013 and held it in 1 quarter. The position peaked at $9K in Q2 2013. 10 funds tracked by Wall St. Rank hold OCRX as of Q3 2013.

  • Guggenheim Capital reported no remaining Ocera Therapeutics, Inc. position as of Q3 2013 after selling out during the quarter.
  • Guggenheim Capital sold 1,622 Ocera Therapeutics, Inc. shares in Q3 2013, an estimated $9K.
  • Guggenheim Capital first reported a position in Ocera Therapeutics, Inc. in Q2 2013 and held it in 1 quarter.
  • Guggenheim Capital's Ocera Therapeutics, Inc. position peaked at $9K in Q2 2013.
  • 10 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q3 2013.

Based on Guggenheim Capital's 13F filing for Q3 2013, filed 14 Nov 2013.